Article Per Year (5 Year)
p-Index From 2020 - 2025
0.61
P-Index
This Author published in this journals
All Journal INDRA: Jurnal Pengabdian kepada Masyarakat Pharmaceutical Sciences and Research (PSR)
Nurrahman, Nani Wijayanti Dyah
Unknown Affiliation
Health Professions Medicine & Pharmacology

Published : 4 Documents Claim Missing Document
Claim Missing Document
Check
Articles

Found 4 Documents
Search

 1 
Evaluation of Category I of Anti-tuberculosis Therapy in Intensive Phase Pulmonary TB by Conversion of Acid-Fast Bacilli Sputum Putra, Oki Nugraha; Damayanti, Amitasari; Nurrahman, Nani Wijayanti Dyah; Devi, Tsania; Aluf, Wildatul
Pharmaceutical Sciences and Research Vol. 6, No. 3
Publisher : UI Scholars Hub

Show Abstract | Download Original | Original Source | Check in Google Scholar

Abstract

Acid fast bacilli (AFB) sputum microscopy is used to diagnose tuberculosis (TB) and to evaluate the effectiveness of anti-tuberculosis drugs in TB eradication program. The AFB sputum microscopy should be performed before treatment, two months after intensive phase and four months after advance phase treatment. The aim of this study was to evaluate the sputum conversion rate of AFB in pulmonary TB patients who received category I of antituberculosis (anti-TB) drugs. Evaluation of sputum conversion was perfomed before initation of anti TB drugs and at the end of the intensive phase. This cohort prospective study was done from February to May, 2018. Nine pulmonary TB patients fulfilled the criteria during the study. This AFB sputum microscopy was evaluated by using Ziehl Neelsen and read by means of International Union Against Tuberculosis and Lung Disease (IUATLD) scale. Nine sputum smear positive were followed for two months. After two months (end of the intensive phase), the smear conversion rate was 100%. All patients received standard dose of anti-TB drugs in fix dose combination (FDC). It can be concluded that the sputum conversion of AFP in pulmonary TB patients who received category I of anti-TB was success at the second month of intensive phase.
A Mini Review : Clinically Significant Potential Drug-Drug Interactions In COVID-19 and Comorbid Therapy Faizah, Ana Khusnul; Nurrahman, Nani Wijayanti Dyah; Putra, Oki Nugraha
Pharmaceutical Sciences and Research Vol. 7, No. 4
Publisher : UI Scholars Hub

Show Abstract | Download Original | Original Source | Check in Google Scholar

Abstract

Coronavirus disease 2019 (COVID-19) is a disease caused by severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) and can be aggravated by comorbid diseases. In administering COVID-19 therapy, we need to consider potential drug-drug interactions (pDDIs) with comorbid drugs. Most patients with comorbid diseases get polypharmacy, therefore the risk of pDDIs increases. Potential drug-drug interactions can cause unwanted effects such as toxicity to death. There is no on-label therapy for COVID-19 but FDA has Emergency Use Authorization (EUA) for hydroxychloroquine, chloroquine, azithromycin, remdesivir, ritonavir, and lopinavir. Some COVID-19 treatment potential drug-drug interactions have a level of severity C and D, so there is a high need for close monitoring during drug administration or modification therapy.
Chloroquine: An Old to be Repurposed Drug For COVID-19 Infection (Risk and Benefit) Putra, Oki Nugraha; Faizah, Ana Khusnul; Nurrahman, Nani Wijayanti Dyah; Hardiyono, Hardiyono
Pharmaceutical Sciences and Research Vol. 7, No. 4
Publisher : UI Scholars Hub

Show Abstract | Download Original | Original Source | Check in Google Scholar

Abstract

Severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) causes Coronavirus Disease 2019 (COVID-19) with a high rate of mortality. Chloroquine and hydroxychloroquine have been used for antimalarial and autoimmune diseases for many years. Due to low toxicity and well tolerability as well as immunomodulatory properties, these drugs are proposed to treat viral infection. Some studies, both in vitro and in a clinical setting, have been evaluated for their ability to treat SARS- CoV-2 as promising therapies. Although The National Agency of Drugs and Food Control of The Republic of Indonesia issued emergency authorization for chloroquine and hydroxychloroquine to be used against COVID-19 infection, the efficacy of these drugs is still based on small clinical non- randomized trials with a limited number of patients. However, the use of these drugs without any risks. The safety of these drugs to be used in COVID-19 patients is lacking. Some experts noticed that the drugs cause harmful adverse effects, especially a harmful QT prolongation. In Indonesia, until now, no study evaluates the effectiveness as well as the safety of these drugs to be used in COVID-19 infection. This article will discuss the role of chloroquine or hydroxychloroquine and its safety to be used against COVID-19 infection.
Pendampingan pembuatan herbal instan temulawak bagi ibu-ibu UMKM jamu di daerah pesisir pantai Kenjeran Faizah, Ana Khusnul; Praditapuspa, Ersanda Nurma; Nurrahman, Nani Wijayanti Dyah; Kurniawan, Wishnu
INDRA: Jurnal Pengabdian kepada Masyarakat Vol. 5 No. 1 (2024): April
Publisher : Universitas Mataram

Show Abstract | Download Original | Original Source | Check in Google Scholar | DOI: 10.29303/indra.v5i1.314

Abstract

The community is focusing on health drinks which can be utilised as health drinks to achieve community health. However, a number of issues were discovered in partners who produced herbal beverage preparations; as these preparations lack preservatives, they don't survive enough. Making fast herbal preparations that have the same qualities as traditional herbal preparations would help them last longer without sacrificing taste or convenience for users. Partners created instant herbal preparations, examined the flow qualities and flow content, and gained a better understanding of how to produce instant herbs and high-quality herbal medicine as a result of this work.
Co-Authors Aluf, Wildatul Anak Agung Istri Sri Wiadnyani Damayanti, Amitasari Devi, Tsania Praditapuspa, Ersanda Nurma Putra, Oki Nugraha Wishnu Kurniawan, Wishnu